Glenmark partners Cyndea to develop soft-gelatin capsule
Glenmark says it has entered into an agreement with Cyndea for developing generic soft-gelatin capsule formulations of certain pharmaceutical products
New Delhi: Drug major Glenmark Pharmaceuticals on Wednesday said it has entered into an agreement with Cyndea Pharma for developing generic soft-gelatin capsule formulations of certain pharmaceutical products.
In a BSE filing, Glenmark Pharmaceuticals said it has “entered into a development, license, manufacture and commercial supply agreement with Cyndea Pharma S L, granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products”.
Under this agreement, Glenmark receives exclusive rights to the US and Canada markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales.
In addition, the agreement provides for the companies to add further soft-gelatin product candidates for development and commercialisation, as new branded softgelatin capsule-based drug products become available in the marketplace, Glenmark added.
Glenmark Pharmaceuticals president, North America, Global API Robert Matsuk said as many as 70% of small molecule pharmaceuticals are difficult for the body to absorb, which leads to challenges in developing effective oral formulations for these medicines.
“The use of soft-gelatin capsules have wide applications to improve absorption and bio-availability of these medicines. Accessing this formulation and manufacturing technology with our strategic partner Cyndea will support Glenmark’s continued mission of providing important and cost-effective generic medicines to patients,” he added.
Shares of Glenmark Pharmaceuticals were trading up 1.84% at Rs704.35 on the BSE.
- Change M&A norms to calculate spectrum dues: Trai
- Cracking India’s bankruptcy code
- RBI’s registry will help solve problem of credit shortage: iSpirt’s Sharad Sharma
- Fintech regulation at an inflection point: Shardul Amarchand’s Shilpa Mankar Ahluwalia
- Voice and AI biggest transformative tech, says EY’s Mahesh Makhija
Editor's Picks »
- Modi slams opposition, refers to Rahul’s ‘unwanted hug’ at Shahjahanpur rally
- Gold price maintains uptrend on global cues, jewellers’ buying
- Sky is Comcast’s final prize as Disney battle approaches endgame
- Donald Trump and the US dollar: Actions speak louder than words
- Jagan Reddy calls Andhra bandh on 24 July over special status
- What ABB India’s performance in June quarter says about capex growth
- Bajaj Finance does well in Q1 even as competition hots up
- Kotak Mahindra Bank: The perils of being priced to perfection
- Higher cane price crushes hopes of sugar mills
- Market optimism before 2019 general election: History may not repeat itself